

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently amended) A method for enhancing cytotoxicity elicited by a therapeutic antibody in a subject, which method comprises disrupting activation of SHIP by Fc-gamma-receptor IIB (FcγRIIB) caused by binding of the antibody to FcγRIIB, wherein the disrupting is accomplished by modifying the Fc region of the antibody to reduce its affinity for FcγRIIB, thereby inhibiting binding of the antibody to FcγRIIB in the subject.
2. Canceled.
3. (Withdrawn) The method according to claim 2, wherein antibody binding is inhibited by a competitive inhibitor.
4. Canceled.
5. (Withdrawn) The method according to claim 1, wherein SHIP activation by FcγRIIB is disrupted by inhibiting the expression of FcγRIIB.
6. (Withdrawn) The method according to claim 5, wherein FcγRIIB expression is disrupted with an antisense nucleic acid specific for the γIIB chain mRNA.
7. (Withdrawn) The method according to claim 5, wherein FcγRIIB expression is disrupted with an intracellular antibody specific for the γIIB chain.

8. (Withdrawn) The method according to claim 1, wherein SHIP activation is inhibited by an inositol phosphatase inhibitor.

9. (Withdrawn) The method according to claim 1, wherein SHIP activation is inhibited by inhibiting SHIP expression.

10. (Original) The method according to claim 1, wherein the antibody is an anti-tumor antibody.

11. (Original) The method according to claim 10, wherein the antibody is specific for a tumor cell growth receptor.

12. (Original) The method according to claim 11, wherein the antibody is specific for a HER2/neu growth factor receptor.

13. (Original) The method according to claim 11, wherein the antibody is specific for a CD20 B cell antigen.

14. (Currently amended) The method according to claim 1, wherein the antibody binds to [[human]] activating Fc receptors.

15. (Original) The method according to claim 14, wherein the subject expresses human Fc receptors.

16. (Withdrawn) An antibody with a variant Fc region, which antibody binds FcγRIIB with reduced affinity.

17. (Withdrawn) The antibody of claim 16, which binds activating Fc-receptors with at least the same affinity as wildtype antibody.

18. (Withdrawn) The antibody of claim 16, which is an anti-tumor antibody.

19. (Withdrawn) The antibody of claim 18, which is specific for a tumor cell growth receptor.

20. (Withdrawn) The antibody of claim 19, which is specific for a HER2/neu growth factor receptor.

21. (Withdrawn) The antibody of claim 19, which is specific for a CD20 B cell antigen.

22. (New) The method according to claim 14, wherein antibody binding is inhibited by modifying the Fc region of the antibody to reduce its affinity for FcγRIIB, while maintaining or increasing its affinity for the activating Fc receptors.